| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -88,710,781 | - |
| Depreciation | 1,077,716 | 727,518 |
| Amortization of operating lease right-of-use assets | 1,157,060 | 757,602 |
| Change in fair value of common stock warrant liabilities | 20,680,868 | - |
| Non-cash stock-based compensation | 2,991,227 | 2,234,141 |
| Non-cash interest on senior convertible notes | 0 | 0 |
| Amortization of discounts on investments | -50,867 | 13,003 |
| Loss on sales of short-term investments | -890,888 | -707,984 |
| Loss on disposal of fixed assets | 0 | 0 |
| (gain) loss on equity investment in affiliated entity | 881,886 | - |
| Net unrealized gain on available-for-sale equity securities | 1,104,782 | - |
| Accounts receivable from affiliated entity | -220,466 | -358,744 |
| Prepaid expenses and other current assets | 881,069 | 1,789,912 |
| Other assets | 32,822 | 32,822 |
| Accounts payable and accrued expenses, including due to affiliated entity | -1,847,935 | -1,497,805 |
| Accrued clinical trial expenses | -1,065,890 | -510,876 |
| Operating lease right-of-use assets and liabilities, net | -1,844,960 | -1,206,959 |
| Grant funding liability, including from affiliated entity | 42,152 | 0 |
| Net cash used in operating activities | -69,258,881 | -47,685,386 |
| Purchases of investments | 4,946,073 | 4,946,073 |
| Proceeds from sale or maturity of investments | 19,201,873 | 10,266,689 |
| Purchases of capital assets | 158,254 | 90,303 |
| Net cash provided by investing activities | 14,097,546 | 5,230,313 |
| Repayment of convertible senior notes | 0 | 0 |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | - | 0 |
| Proceeds from issuance of warrants, net of issuance costs-Pre Funded Warrants | 0 | - |
| Proceeds from issuance of common stock, net of issuance costs | 8,287,277 | 1,102,149 |
| Proceeds from issuance of warrants, net of issuance costs-Warrant | 16,986,830 | - |
| Proceeds from exercise of warrants and pre-funded warrants | 752,134 | - |
| Proceeds from stock option exercises | 0 | 0 |
| Taxes paid related to net share settlement of equity awards | -110,783 | -108,996 |
| Net cash provided by financing activities | 25,915,458 | 993,153 |
| Effect of exchange rate changes on cash and cash equivalents | 0 | 0 |
| (decrease) increase in cash and cash equivalents | -29,245,877 | -41,461,920 |
| Cash and cash equivalents at beginning of period | 65,813,297 | - |
| Cash and cash equivalents at end of period | 36,567,420 | - |
INOVIO PHARMACEUTICALS, INC. (INO)
INOVIO PHARMACEUTICALS, INC. (INO)